Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin 9-NC) [rubitecan] Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients.

Next Previous
X
Search
Trial Profile

Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin 9-NC) [rubitecan] Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rubitecan (Primary) ; Fluorouracil; Gemcitabine; Mitomycin
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Astex Pharmaceuticals

    • Most Recent Events

    • 23 Jul 2008 Astex Pharmaceuticals added as trial associate as reported by ClinicalTrials.gov.
    • 23 Jul 2008 Trial Centre updated as reported by ClinicalTrials.gov.
    • 04 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top